IL315800A - Preparations and methods for the treatment of cancer - Google Patents
Preparations and methods for the treatment of cancerInfo
- Publication number
- IL315800A IL315800A IL315800A IL31580024A IL315800A IL 315800 A IL315800 A IL 315800A IL 315800 A IL315800 A IL 315800A IL 31580024 A IL31580024 A IL 31580024A IL 315800 A IL315800 A IL 315800A
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- methods
- treating cancer
- cancer
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263323339P | 2022-03-24 | 2022-03-24 | |
| PCT/US2023/016132 WO2023183520A1 (en) | 2022-03-24 | 2023-03-23 | Compositions and methods for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL315800A true IL315800A (en) | 2024-11-01 |
Family
ID=88102078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL315800A IL315800A (en) | 2022-03-24 | 2023-03-23 | Preparations and methods for the treatment of cancer |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20250206728A1 (https=) |
| EP (1) | EP4499625A4 (https=) |
| JP (1) | JP2025509965A (https=) |
| KR (1) | KR20250005157A (https=) |
| CN (2) | CN119522217A (https=) |
| AU (1) | AU2023241042A1 (https=) |
| CA (1) | CA3246244A1 (https=) |
| IL (1) | IL315800A (https=) |
| TW (1) | TW202400575A (https=) |
| WO (1) | WO2023183520A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4499625A4 (en) | 2022-03-24 | 2026-03-18 | A2A Pharmaceuticals Inc | CANCER COMPOSITIONS AND TREATMENT METHODS |
| TW202530204A (zh) * | 2023-09-27 | 2025-08-01 | 美商Ａ２Ａ製藥公司 | 用於治療與轉化酸性捲曲螺旋蛋白相關的癌症的方法 |
| WO2026026956A1 (zh) * | 2024-08-02 | 2026-02-05 | 北京康辰药业股份有限公司 | Tacc抑制剂化合物、药物组合物及其制备方法和应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
| EP1794135A1 (en) * | 2004-09-27 | 2007-06-13 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| US20080207572A1 (en) | 2005-07-14 | 2008-08-28 | Ab Science | Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma |
| EP2043651A2 (en) | 2006-07-05 | 2009-04-08 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
| US20130023534A1 (en) | 2010-03-26 | 2013-01-24 | Casillas Linda N | Pyrazolyl-pyrimidines as kinase inhibitors |
| JP5947818B2 (ja) * | 2011-03-02 | 2016-07-06 | リード ディスカバリー センター ゲーエムベーハー | 薬学的活性化二置換ピリジン誘導体 |
| PE20142098A1 (es) * | 2012-01-06 | 2015-01-08 | Agios Pharmaceuticals Inc | Compuestos terapeuticamente activos y sus metodos de uso |
| JP6008305B2 (ja) | 2012-05-02 | 2016-10-19 | 公益財団法人がん研究会 | Ｔａｃｃ３を標的とする小化合物 |
| WO2015082583A1 (en) | 2013-12-05 | 2015-06-11 | F. Hoffmann-La Roche Ag | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality |
| US9796701B2 (en) | 2013-12-31 | 2017-10-24 | Xuanzhu Pharma Co., Ltd. | Kinase inhibitor and use thereof |
| JP6682221B2 (ja) | 2014-09-24 | 2020-04-15 | 公益財団法人がん研究会 | Ｔａｃｃ３阻害剤のスクリーニング方法 |
| EP3070084A1 (en) | 2015-03-18 | 2016-09-21 | Rottapharm Biotech S.r.l. | New fyn kinase inhibitors |
| WO2016173557A1 (zh) | 2015-04-30 | 2016-11-03 | 中国科学院上海药物研究所 | 一类具有激酶抑制活性的化合物、制备方法和用途 |
| MX2017015574A (es) | 2015-06-02 | 2018-08-09 | Pharmacyclics Llc | Inhibidores de tirosina quinasa de bruton. |
| TWI620748B (zh) | 2016-02-05 | 2018-04-11 | National Health Research Institutes | 氨基噻唑化合物及其用途 |
| ES2805976T3 (es) | 2016-06-30 | 2021-02-16 | Janssen Pharmaceutica Nv | Derivados heteroaromáticos en calidad de inhibidores de NIK |
| WO2018045957A1 (zh) | 2016-09-07 | 2018-03-15 | 江苏豪森药业集团有限公司 | 一种cdk4/6抑制剂及其制备方法和应用 |
| WO2018124001A1 (ja) | 2016-12-27 | 2018-07-05 | 国立研究開発法人理化学研究所 | Ｂｍｐシグナル阻害化合物 |
| CN107089968B (zh) | 2017-04-12 | 2019-06-18 | 南方医科大学 | 1-(2-氨基吡啶-4-基)-3-哌啶甲酰胺衍生物及其合成方法和应用 |
| TWI667236B (zh) | 2017-06-13 | 2019-08-01 | 財團法人國家衛生研究院 | 作為蛋白激酶抑制劑的胺基噻唑化合物 |
| MX2020004536A (es) | 2017-11-23 | 2020-08-03 | Biomed X Gmbh | Derivados de pirimidina como inhibidores del receptor de tropomiosina quinasa (trka). |
| JP2021514359A (ja) | 2018-02-15 | 2021-06-10 | ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． | キナーゼ阻害剤としての複素環式化合物 |
| WO2019177374A1 (ko) | 2018-03-13 | 2019-09-19 | 포로노이바이오 주식회사 | 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물 |
| CN112469414A (zh) | 2018-05-25 | 2021-03-09 | 昂科库博疗法有限责任公司 | 作为新型候选抗癌药物的高效力tacc3抑制剂 |
| CN114502536A (zh) | 2019-08-14 | 2022-05-13 | 诺维逊生物股份有限公司 | 作为激酶抑制剂的杂环化合物 |
| CN115279754A (zh) * | 2019-11-14 | 2022-11-01 | A2A制药有限公司 | 靶向tacc3的异恶唑衍生物作为抗癌剂 |
| KR20240005751A (ko) | 2021-04-12 | 2024-01-12 | 에이2에이 파마수티칼스, 잉크. | 암 치료를 위한 조성물 및 방법 |
| EP4198097B1 (en) | 2021-12-15 | 2024-05-29 | Ricoh Company, Ltd. | Image forming method and active energy ray-curable composition set |
| EP4499625A4 (en) | 2022-03-24 | 2026-03-18 | A2A Pharmaceuticals Inc | CANCER COMPOSITIONS AND TREATMENT METHODS |
-
2023
- 2023-03-23 EP EP23775685.3A patent/EP4499625A4/en active Pending
- 2023-03-23 CA CA3246244A patent/CA3246244A1/en active Pending
- 2023-03-23 CN CN202380041923.9A patent/CN119522217A/zh active Pending
- 2023-03-23 AU AU2023241042A patent/AU2023241042A1/en active Pending
- 2023-03-23 WO PCT/US2023/016132 patent/WO2023183520A1/en not_active Ceased
- 2023-03-23 JP JP2024556140A patent/JP2025509965A/ja active Pending
- 2023-03-23 IL IL315800A patent/IL315800A/en unknown
- 2023-03-23 TW TW112110936A patent/TW202400575A/zh unknown
- 2023-03-23 US US18/849,309 patent/US20250206728A1/en active Pending
- 2023-03-23 KR KR1020247035261A patent/KR20250005157A/ko active Pending
- 2023-03-23 CN CN202510379414.8A patent/CN120040441A/zh active Pending
- 2023-11-13 US US18/389,078 patent/US11986475B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4499625A1 (en) | 2025-02-05 |
| JP2025509965A (ja) | 2025-04-11 |
| WO2023183520A1 (en) | 2023-09-28 |
| CN119522217A (zh) | 2025-02-25 |
| US20240156813A1 (en) | 2024-05-16 |
| AU2023241042A1 (en) | 2024-10-10 |
| EP4499625A4 (en) | 2026-03-18 |
| KR20250005157A (ko) | 2025-01-09 |
| CN120040441A (zh) | 2025-05-27 |
| US11986475B1 (en) | 2024-05-21 |
| US20250206728A1 (en) | 2025-06-26 |
| TW202400575A (zh) | 2024-01-01 |
| CA3246244A1 (en) | 2023-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286350A (en) | Preparations and methods for the treatment of cancer | |
| IL288914A (en) | Preparations and methods for the treatment of cancer | |
| ZA202104870B (en) | Methods and compositions for treating cancer | |
| IL315800A (en) | Preparations and methods for the treatment of cancer | |
| EP4025590A4 (en) | METHODS AND COMPOSITIONS FOR TREATING CANCER | |
| IL320332A (en) | Cancer treatment methods | |
| SG11202109336UA (en) | Methods and compositions for treating cancer | |
| IL287982A (en) | Preparations and methods for the treatment of cancer | |
| IL286153A (en) | Methods and preparations for the treatment of cancer | |
| IL309120A (en) | Methods and compositions for the treatment of cancer | |
| IL309071A (en) | Methods and compositions for the treatment of cancer | |
| IL308530A (en) | Preparations and methods for treating lung cancer | |
| EP4149508A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | |
| IL312846A (en) | Methods and preparations for the treatment of cancer | |
| IL299039A (en) | Methods and preparations for the treatment of triple-negative breast cancer | |
| IL319403A (en) | Compositions and methods for treating advanced solid tumors | |
| EP4243835A4 (en) | COMPOSITIONS AND METHODS FOR TREATING SOLID CANCER | |
| IL319543A (en) | Cancer treatment compositions and methods | |
| IL285036A (en) | Methods and preparations for the treatment of cancer | |
| IL316053A (en) | Preparations and methods for the treatment of solid cancer | |
| GB202402730D0 (en) | Methods and compositions for treating cancer | |
| EP4518861A4 (en) | COMPOSITION AND METHOD OF CANCER TREATMENT | |
| CA3296990A1 (en) | Compositions and methods for treating cancer | |
| CA3291233A1 (en) | Methods and compositions for treating cancer | |
| CA3278391A1 (en) | Compositions and methods for treating cancer |